The NHS and NICE have approved expanding Wegovy, a weight loss drug, to overweight and obese patients with certain heart and circulatory conditions to help reduce major cardiovascular events.

Eligibility is broadened to BMI 27 or higher, used alongside statins, diet, and exercise, extending access to about 1.2 million people in England.

About 1.2 million people with cardiovascular disease in England could receive Wegovy to prevent future major cardiovascular events.

Health spokespeople stress a potentially life-saving impact for high-risk individuals and the goal of extending healthier lives while reducing emergency care.

Investors welcomed broader NHS access, with Novo Nordisk shares rising intraday before giving up some gains.

Clinical trials show benefits early in treatment, suggesting cardiovascular effects beyond weight loss.

Experts say the program could lower risk of subsequent heart attacks and strokes, improving survival and quality of life while affecting NHS costs and resource use.

Officials acknowledge a substantial impact on preventing recurrent events and improving life expectancy, while discussing NHS capacity to scale access.

Health officials call the move a potential gamechanger, backed by medical bodies who highlight benefits beyond obesity treatment.

NICE described Wegovy as cost-effective for NHS use, with anticipated availability within months.

Stakeholders emphasize tailoring treatment to stroke survivors, considering alternatives when appropriate, and addressing broader risks like smoking, diet, and activity.

Industry and health groups, including the British Heart Foundation and the National Pharmacy Association, welcome the potential reduction in cardiovascular disease burden.